Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Bristol Myers Squibb, Novartis Pharmaceuticals Corporation, and Taiho Oncology, Inc.

Medical Crossfire®: Improving Patient Outcomes in MDS Through Better Diagnosis, Risk Stratification, and New Treatment Options

Release Date: June 29, 2020
Expiration Date: June 29, 2021

Activity Overview

Treatment options for patients with myelodysplastic syndromes (MDS) have changed rapidly in recent years, for patients across the spectrum of risk stratification. In addition to new therapeutics to manage anemia in low-risk disease and emerging treatments for high-risk MDS, the increasing understanding of molecular alterations in MDS has the potential to impact optimal disease management in the near future. In this online, on-demand Medical Crossfire®, the expert faculty panel participate in an open exchange of ideas and viewpoints in which they review patient scenarios, reflect on how they might handle particular cases, integrate relevant evidence into real-world practice, and compare their patient care approaches. The renowned faculty place key clinical findings in the context of real-world practice to improve knowledge and application of new data to enrich treatment practices for patients with MDS.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Bristol Myers Squibb, Novartis Pharmaceuticals Corporation, and Taiho Oncology, Inc.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational activity is directed toward medical oncologists, hematologists, and other healthcare professionals interested in the treatment of hematologic malignancies.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Explain the current categorization of MDS disease and how risk stratification informs clinical decision-making
  • Determine how individual patient characteristics impact prognosis, including response to therapies, survival, or progression to AML
  • Apply recent evidence concerning novel MDS treatment strategies to practice
  • Outline the mechanism of action of novel therapies under investigation for the treatment of low-to-intermediate and high-risk MDS

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.


Guillermo Garcia-Manero, MD
Guillermo Garcia-Manero, MD
Chief, Section of Myelodysplastic Syndromes
Deputy Chair, Translational Research
Department of Leukemia, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Grant Research Support: BMS, Novartis, Taiho.

Rami Komrokji, MD
Rami Komrokji, MD
Senior Member, Vice Chair
Section Head, Leukemia and MDS
Department of Malignant Hematology
Moffitt Cancer Center
Professor of Oncologic Sciences
University of South Florida
Tampa, FL

Disclosures: Consultant: Acceleron, Agios, Abbvie, Celgene/BMS, Incyte, Pfizer, Jazz Pharma, Novartis, PharmaEssentia; Speakers Bureau: Agios, Celgene/BMS, Jazz Pharma.

Amy E. DeZern, MD, MHS
Amy E. DeZern, MD, MHS
Myelodyplastic Syndrome (MDS) and other Marrow Failure Disorders Division of Hematologic Malignancies
Associate Professor
Department of Oncology
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine
Baltimore, MD

Disclosures: Consultant: Celgene, Astex.

Elizabeth A. Griffiths, MD
Elizabeth A. Griffiths, MD
Associate Professor
Leukemia Division
Roswell Park Comprehensive Cancer Center
State University of NY at Buffalo
Buffalo, NY

Disclosures: Grant Research Support: Genentech, Inc., Alexion, Astex/Otsuka; Consultant: Novartis, Abbvie, Celgene/BMS, Alexion Pharmaceuticals, Potomac Center for Medical Education, Boston Biomedical.

Rashmi Kanagal-Shamanna, MD
Rashmi Kanagal-Shamanna, MD
Associate Professor, Hematopathology
Director of Microarray, Molecular Diagnostics Laboratory
Dept. of Hematopathology, Division of Pathology & Lab Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas, USA

Disclosures: Rashmi Kanagal-Shamanna, MD has no relevant financial relationships with commercial interests to disclose.

The staff Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By